Due to the reliance of EWS::FLI1 on chromatin remodeling complexes, there is great interest in targeting Ewing sarcoma and the fusion specifically using epigenetic drugs including agents that inhibit HDACs (HDACi) (149), bromodomain proteins (BETi) (73, 150–152), LSD1 (LSD1i) (49, 72), and KDM3A (JIB-04) (153). Here, FLI1 is linked to Ewing sarcoma.